These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28444816)

  • 21. Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.
    Riccardi N; Del Puente F; Taramasso L; Di Biagio A
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218821657. PubMed ID: 30798670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of a Triple-Therapy Regimen in a Critically Ill Patient with HIV.
    Turley SL; Fulco PP
    J Int Assoc Provid AIDS Care; 2017; 16(2):117-119. PubMed ID: 28198203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.
    Borghetti A; Baldin G; Ciccullo A; Gagliardini R; D'Avino A; Mondi A; Ciccarelli N; Lamonica S; Fanti I; Trecarichi E; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2016 Aug; 71(8):2359-61. PubMed ID: 27147306
    [No Abstract]   [Full Text] [Related]  

  • 24. Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma.
    Cozzi V; Charbe N; Baldelli S; Castoldi S; Atzori C; Cattaneo D; Clementi E
    Ther Drug Monit; 2016 Jun; 38(3):407-13. PubMed ID: 26885814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
    Penrose KJ; Parikh UM; Hamanishi KA; Else L; Back D; Boffito M; Jackson A; Mellors JW
    J Infect Dis; 2016 Mar; 213(6):1013-7. PubMed ID: 26563240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment.
    Cattaneo D; Capetti A; Rizzardini G
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):245-252. PubMed ID: 30704313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
    Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
    Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
    Curran A; Rojas J; Cabello A; Troya J; Imaz A; Domingo P; Martinez E; Ryan P; Górgolas M; Podzamczer D; Knobel H; Gutiérrez F; Ribera E
    J Antimicrob Chemother; 2016 Dec; 71(12):3510-3514. PubMed ID: 27591292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabotegravir and rilpivirine for the treatment of HIV.
    Rial-Crestelo D; Pinto-Martínez A; Pulido F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
    Bollen P; Reiss P; Schapiro J; Burger D
    Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabotegravir Plus Rilpivirine: First Approval.
    Markham A
    Drugs; 2020 Jun; 80(9):915-922. PubMed ID: 32495274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triumeq--a 3-drug combination for HIV.
    Med Lett Drugs Ther; 2015 Jan; 57(1459):7-8. PubMed ID: 25555073
    [No Abstract]   [Full Text] [Related]  

  • 33. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
    Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
    J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV: new drugs, new guidelines.
    Geretti AM; Tsakiroglou M
    Curr Opin Infect Dis; 2014 Dec; 27(6):545-53. PubMed ID: 25304395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.
    Kirtane AR; Abouzid O; Minahan D; Bensel T; Hill AL; Selinger C; Bershteyn A; Craig M; Mo SS; Mazdiyasni H; Cleveland C; Rogner J; Lee YL; Booth L; Javid F; Wu SJ; Grant T; Bellinger AM; Nikolic B; Hayward A; Wood L; Eckhoff PA; Nowak MA; Langer R; Traverso G
    Nat Commun; 2018 Jan; 9(1):2. PubMed ID: 29317618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation and pharmacology of long-acting rilpivirine.
    Williams PE; Crauwels HM; Basstanie ED
    Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
    Pialoux G; Marcelin AG; Cawston H; Guilmet C; Finkielsztejn L; Laurisse A; Aubin C
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):83-91. PubMed ID: 28741965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
    Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
    Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease.
    Moltó J; Graterol F; Miranda C; Khoo S; Bancu I; Amara A; Bonjoch A; Clotet B
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2564-6. PubMed ID: 26856824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rilpivirine: The Key for Long-term Success.
    Viciana P
    AIDS Rev; 2017; 19(3):156-166. PubMed ID: 29066858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.